STOCK COMMENTS / EPS CHANGESCelgene ( CELG) target raised at Jefferies to $91, Jefferies said. Positive topline data for Abraxane. Buy rating. Chemed Corporation ( CHE) target raised at Oppenheimer to $80, Oppenheimer said. Bullish following management meetings. Outperform rating. CNO Financial ( CNO) cut from Conviction Buy List at Goldman. Valuation call, as the stock is up 41% since June. $11 price target. Express ( EXPR) estimates, target reduced at BMO. Shares of EXPR now seen reaching $15, according to BMO Capital. Estimates also cut, given the company's new guidance. Outperform rating. Halliburton ( HAL) numbers lowered at Jefferies. Shares of HAL now seen reaching $44, Jefferies said. Estimates also lowered on North America weakness. Buy rating. Helmerich & Payne ( HP) numbers lowered at Jefferies. Shares of HP now seen reaching $55, Jefferies said. Estimates also lowered on North American weakness. Buy rating. Medivation ( MDVN) numbers raised at Citigroup. Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating. Mosaic ( MOS) numbers cut at Citigroup. Shares of MOS now seen reaching $69, Citigroup said. Estimates also lowered on disappointing quarterly results. Buy rating. MSCI ( MSCI) estimates, target reduced at Credit Suisse. MSCI estimates were cut through 2014, Credit Suisse said. Vanguard loss will cut into profits. Outperform rating and new $31 price target. AT&T ( T) estimates trimmed at UBS through 2012 on higher iPhone sales, UBS said. Neutral rating and $35 price target. Zillow ( Z) estimates, target increased at ThinkEquity. Z estimates were raised through 2013, ThinkEquity said. Strong agent demand will improve pricing power. Buy rating and new $49 price target. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.